Abstract 10021: Oral Lycopene Supplementation Improves Endothelial Function in Patients with Cardiovascular Disease: A Randomised Controlled Trial
Introduction A ‘Mediterranean diet’ rich in antioxidants may reduce the incidence of cardiovascular disease (CVD). Lycopene is a potent antioxidant and carotenoid component in tomatoes. Association studies show an inverse relation between plasma and adipose lycopene concentrations and risk of CVD. We hypothesised that a standardised preparation of lycopene (Ateronon) would improve endothelial function assessed by forearm plethysmography, which correlates independently to CVD outcomes.
Methods 36 healthy volunteers (HV) and 36 stable CVD patients (previous atherosclerotic event, on optimal therapy including statins) were randomised unequally (2:1) to either 7mg lycopene or placebo daily for 2 months (Clintrials ID: NCT01100385). Forearm blood flow responses to intra-arterial infusions of acetylcholine, (endothelium dependent vasodilatation; EDV), sodium nitroprusside, (endothelium independent vasodilatation; EIDV), and NG-monomethyl-L-arginine (measuring basal nitric oxide; NO) were measured using venous plethysmography.
Results At baseline, CVD and HV groups were similar in age (67 ± 5 vs. 64 ± 11), blood pressure and hs-CRP but the CVD group had a lower LDL (93mg/dl ± 23 vs. 139mg/dl ± 35, P<0.001). The CVD group had impaired EDV to ACh compared with HV (30% lower; 95% CI: -45, -10, P=0.008). Lycopene improved EDV in CVD patients by 53% (95% CI: +9, +93, P=0.03 vs. placebo - see figure) independent of changes in EIDV or basal NO responses. Lycopene did not change EIDV, EDV or basal NO responses in HV. Home blood pressure, LDL, HDL and hs-CRP levels did not change in both groups. In a post-hoc analysis; after lycopene treatment, CVD patients showed no difference in EDV response compared to HV at baseline (3% lower; 95% CI: -30, +30, P=0.85), suggesting normalization of vascular function.
Conclusions Lycopene supplementation improves endothelial function in patients with CVD, and this may require further investigation in a larger outcome study.
- © 2012 by American Heart Association, Inc.